An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Clinical trial NCT05643170 · TERMINATED
Trial details
- NCT number
- NCT05643170
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-08
- Primary completion
- 2023-03-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.